Comparison of PET/MRI with Multiparametric MRI in Diagnosis of Primary Prostate Cancer: A Meta-analysis

Publication date: Available online 21 February 2019

Source: European Journal of Radiology

Author(s): Mou Li, Zixing Huang, Haopeng Yu, Yi Wang, Yongchang Zhang, Bin Song

Abstract

Objective

This meta-analysis aimed to compare the diagnostic performance of positron emission tomography (PET)/MRI using various radiotracers with multiparametric (mp) MRI for detection of primary prostate cancer (PCa).

Methods

A systematic literature search up to January 2019 was performed to identify studies that evaluated the diagnostic value of PET/MRI and mpMRI for detection of PCa in the same patient cohorts and had sufficient data to construct 2 × 2 contingency tables for true-positive (TP), false-positive (FP), false-negative (FN), and true-negative (TN) results. The quality of each study was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 tool, and pooled sensitivity (SEN) and specificity (SPE) were calculated. Summary receiver operating characteristic (ROC) curves and area under the curves (AUCs) were used to compare the performances of PET/MRI and mpMRI.

Results

We identified 9 eligible studies that included a total of 353 patients. PET/MRI had a SEN of 0.783 (95% CI, 0.758–0.807) and a SPE of 0.899 (95% CI, 0.879–0.917), and mpMRI had a SEN of 0.603 (95% CI, 0.574–0.631) and a SPE of 0.887 (95% CI, 0.866–0.906). PET/MRI had a higher AUC than mpMRI (0.9311, 95% CI, 0.8990–0.9632vs. 0.8403, 95% CI, 0.7864–0.8942; P =  0.0036). There was no notable publication bias, but there was medium heterogeneity in outcomes. The meta-regression analysis showed the major potential cause of heterogeneity was the use of region-based rather than lesion-based analysis.

Conclusion

PET/MRI has very good diagnostic performance and outperforms mpMRI for the diagnosis of primary PCa.

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2Eoh5iG